Meghana Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.60 Cr
- Paid Up Capital ₹ 1.60 Cr
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2011
- Open Charges ₹ 2.59 Cr
- Satisfied Charges ₹ 1.72 Cr
About Meghana Pharma
Meghana Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 June 2007 and has a history of 17 years and eight months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Environment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2011. It's a company limited by shares with an authorized capital of Rs 1.60 Cr and a paid-up capital of Rs 1.60 Cr.
The company currently has active open charges totaling ₹2.59 Cr. The company has closed loans amounting to ₹1.72 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jonnala Latha and Tiyyagura Vijaya serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232TG2007PTC054442
- Company No.
054442
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2007
- Date of AGM
30 Sep 2011
- Date of Balance Sheet
31 Mar 2011
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Meghana Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jonnala Latha  | Director | 14-Jun-2007 | Current |
| Tiyyagura Vijaya | Director | 22-Mar-2013 | Current |
Financial Performance of Meghana Pharma.
Enhance accessibility to Meghana Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Meghana Pharma?
Unlock access to Meghana Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹2.59 Cr
₹1.72 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 2.59 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Feb 2012 | State Bank Of India | ₹2.59 Cr | Open |
| 27 Nov 2007 | Andhra Bank | ₹1.72 Cr | Satisfied |
How Many Employees Work at Meghana Pharma?
Unlock and access historical data on people associated with Meghana Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meghana Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meghana Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
